Mind Medicine (MindMed) Inc. (MNMD)
NASDAQ: MNMD · Real-Time Price · USD
8.19
-0.78 (-8.70%)
At close: Nov 12, 2024, 4:00 PM
8.12
-0.07 (-0.85%)
After-hours: Nov 12, 2024, 7:35 PM EST
Mind Medicine (MindMed) Stock Forecast
Stock Price Forecast
The 8 analysts with 12-month price forecasts for MNMD stock have an average target of 28.75, with a low estimate of 14 and a high estimate of 55. The average target predicts an increase of 251.04% from the current stock price of 8.19.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for MNMD stock from 9 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jun '24 | Jul '24 | Aug '24 | Sep '24 | Oct '24 | Nov '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 4 | 3 | 4 | 4 | 4 |
| Buy | 5 | 5 | 5 | 5 | 5 | 5 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 8 | 9 | 8 | 9 | 9 | 9 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $55 | Strong Buy | Reiterates | $55 | +571.55% | Nov 11, 2024 |
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $16 → $14 | Strong Buy | Maintains | $16 → $14 | +70.94% | Sep 16, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $35 → $55 | Strong Buy | Maintains | $35 → $55 | +571.55% | Aug 29, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $35 | Strong Buy | Reiterates | $35 | +327.35% | Jul 31, 2024 |
| Roth MKM | Roth MKM | Strong Buy Maintains $36 | Strong Buy | Maintains | $36 | +339.56% | Jul 24, 2024 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-1.59
from -2.44
EPS Next Year
-1.39
from -1.59
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | n/a | n/a | n/a | ||
| Avg | n/a | n/a | n/a | ||
| Low | n/a | n/a | n/a |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -1.28 | -1.09 | -1.04 | ||
| Avg | -1.59 | -1.39 | -1.52 | ||
| Low | -1.86 | -1.56 | -1.87 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.